Global Cancer Technology, Inc holds licenses to patents and Intellectual Property for 5 separate and unique medical technologies. The Company will commercialize these technologies by setting up subsidiary companies. The Company seeks to fund each of these technologies through the subsidiary that is formed. Global Cancer Technology, Inc owns a majority of each subsidiary.
A patented drug delivery process that attaches a prodrug to a nano Crystal scintillator that is then activated at the tumor site with radiosurgery
Attaching a prodrug to a nanocrystal Scintillator
For decades, medical radiation specialists have sought to activate by local radiation beams, a non-toxic, interactive version of a cancer drug, (pro-drug) selectively at cancers and not body tissues in general. This strategy is attractive because it aims to overwhelm tumor resistant mechanisms by allowing high drug concentrations at tumor foci, while sparing normal tissue and organs from toxicity, and reducing the generally damaging radiation doses needed to control tumor burden. Drug activity focused on areas adjacent to tumors that would destroy the micro metastasis that are so challenging to selectively excise or treat would be desirable. Single cell infiltration that significantly diminishes by a blading the active margin of primary and secondary tumors, especially in early disease stages, would also be desirable. Intravenously injected nanoparticles may concentrate at tumor foci by leaking through typically incomplete tumor vessels, by adhering to tumor micro vessels via well-establishedtargeting ligands, and penetrating the blood brain barrier both passively and actively via transferred ligands.
A modification of UCN-01 for improved PK.
UCI – pursuing reformulation via structural modification (pegylation) to avoid plasma proteins. So, the pegylation prevents binding to AAG and thus the UCN-01, which is still active, can enter tumors.
UCN-01 even in non-cytotoxic doses markedly sensitizes tumor cells to radiation and chemotherapeutics, a characteristic that has led to over 400 papers and 22 NIH sponsored UCN-01 Phase I-III patient trials. However, a serious drawback of UCN-01 that has stymied its preclinical development is that it avidly binds the human plasma protein AAG, leaving insufficient free (active) compound. Our effort is to pursue reformulation via structural modification (pegylation) to avoid plasma proteins. So, the pegylation prevents binding to AAG and thus the UCN-01, which is still active, can enter tumors.
Global Cancer Technology had acquired a third patent and intellectual property from the University of California San Diego and the John Moores Cancer Center. Global Cancer Technology has developed another subsidiary called NanoMed Tracking, Inc., which will bring to market:
A method to label and track hospital instruments with nano Quantum Dots
A patented process to label and track hospital instruments utilizing nano quantum dots
A method to label and track hospital instruments utilizing nano Quantum Dots and advanced optical recording technology
Our system consists of an ink-jet polymer coating application device and an Optical reader for identifying and tracking disposable object and surgical instruments in surgical operating rooms. Highlights of our system include; the system for identifying and tracking a surgical object comprises a tag identifier including object information encoded on a fluorescent paint coating attached to a surgical object: a detector disposed to receive a reflection of the fluorescent paint from the tag identifier: a receiver in communication with the detector receiving a single transmitted by the detector wherein the signal is generated by the reflection of the tag identifier. The tag identifier comprises one or more quantum dots arranged to define a spectral signature: and a layer coating compromising the one or more quantum dots, wherein the layer coating is attached to an object. The FDA is requiring that hospitals must have a surgical instrument tracking system in place by September 2020. Currently less than 5% of hospitals have a system to track instruments.
Global Cancer Technology has acquired the exclusive worldwide rights from American Radiosurgery, Inc. to distribute the RGS Orbiter, which will be the first gamma based radiosurgery device that can treat tumors of the brain as well as the rest of the body. The RGS Orbiter will treat tumors within the brain exactly like a gamma knife, but can also now treat tumors of the breast, prostate etc. etc. the RGS Orbiter will not only be successful in the United States, but in international markets as well.
The first gamma-based radiosurgery system that can treat tumors of the brain as well as the rest of the body.
The Rotating Gamma System (RGS Orbiter) is a newly designed Cobalt-60 based radiosurgery Gamma System and capable of treating small and mid-size lesions of the total body of the patient. The patient is fixed to the treatment table with an immobilization device to avoid any patient movement during treatment. In case of a skull treatment the patient’s head is immobilized via a standard stereo tactic head frame. When other parts of the patient are treated the fixation, device is an inflatable body shell. The precision of treatment achievable in the skull region is therefore about 0.5 mm when the stereotactic frame is used; the precision in other body locations using the inflatable immobilization is about 2mm.The treatment head houses 42 sources of Cobalt-60 arranged in one line over a circular segment of +/- 25 degrees as seen from the isocenter around the patient’s length axis, if the table is in the home position. The source isocenter distance is 469 mm.The table is in its “home” position, when the length axis of the table is aligned within the center plane of the “C arm” structure. The table can rotate around a vertical axis (“B axis”) through the isocenter of + /- 90 degrees. The table also can be moved in the 3-linear coordinate axis x, y and z.During treatment, the treatment head of the machine, containing the 42 sources moves from the head “home” position, this is the “0 degree” top vertical position to the lowest position at 180 degree around the horizontal “C” axis and back to the “0” position. This movement is a semi-circle arching with speeds between 0 and 6 degree per second. Therefore 6 different mechanical movements are involved:
- Moving of the treatment head in semi circles from 0 to 180 degrees and back. The numbers of executed semi circles are dependent on the total treatment time.
- Rotational movement of the patient table around the vertical axis.
- X, Y and Z movement of the table.
- Beam “on” and Beam “off” movement.
All mechanical movements are computer controlled and depending on the chosen treatment plan one or all possible mechanical movements are executed during treatment to simulate a 360-degree rotational treatment, half of the treatment time the patient table would be in the minus 90-degree position and half of the treatment time in the plus 90-degree position, while the treatment head moves “down” and “up” in the semi-circle.The RGS Vertex Orbiter consists of the gamma-ray treatment unit, the control system, protection and safety system, the stereo-tactic localization system, and the treatment planning system. The treatment planning system connects to the diagnostic imaging devices and allows downloading of the treatment parameter to the RGS Vertex Orbiter.